Digestive Diseases and Sciences

, Volume 53, Issue 5, pp 1246–1251 | Cite as

Small Intestinal Bacterial Overgrowth in Patients with Interstitial Cystitis and Gastrointestinal Symptoms

  • Leonard B. Weinstock
  • Carl G. Klutke
  • Henry C. Lin
Original Paper


Purpose Interstitial cystitis (IC) often coexists with irritable bowel syndrome (IBS). IBS may be explained by small-intestinal bacterial overgrowth (SIBO), which increases immune activation and visceral hypersensitivity. This prospective pilot study tested hypotheses that IC patients with gastrointestinal (GI) symptoms have SIBO, that nonabsorbable antibiotic use improves symptoms, and that improvement is sustained by prokinetic therapy. Methods Consecutive IC patients with GI symptoms had lactulose breath testing (LBT). Those with abnormal results received rifaximin 1,200–1,800 mg/day for 10 days then tegaserod 3 mg/nightly. Questionnaires addressed IC and GI global improvement. Results Of 21 patients, 17 (81%) had abnormal LBTs. Of 15 patients treated, GI global improvement was moderate to great in 11 (73%) and sustained in ten (67%). IC global improvement was moderate to great in six (40%) and sustained in seven (47%). Conclusions A majority of IC patients and GI symptoms had an abnormal LBT suggesting SIBO. Rifaximin improved symptoms, which was sustained by tegaserod.


SIBO Interstitial cystitis IBS Rifaximin 



Dr. Lin’s work is supported by the Jill and Tom Barad Family Fund. No commercial financial support was received for the conduct of this study. Speaker’s Bureau: Salix and Novartis (Weinstock, Lin); IP rights (Lin).


  1. 1.
    Nickel JC (2004) Interstitial cystitis: a chronic pelvic pain syndrome. Med Clin North Am 88:467–481Google Scholar
  2. 2.
    Giamberardino M (2000) Sex-related and hormonal modulation of visceral pain. In: Fillingim R (ed) Sex gender and pain, vol 17. IASP Press, SeattleGoogle Scholar
  3. 3.
    Lin HC (2004) Small intestinal bacterial overgrowth: a framework for understanding irritable bowel syndrome. JAMA 292:852–858PubMedCrossRefGoogle Scholar
  4. 4.
    Ritchie J (1973) Pain from distension of the pelvic colon by inflating a balloon in the irritable bowel syndrome. Gut 6:105–112Google Scholar
  5. 5.
    Fitzgerald MP, Koch D, Senka J (2005) Visceral and cutaneous sensory testing in patients with painful bladder syndrome. Neurourol Urodyn 24:627–632PubMedCrossRefGoogle Scholar
  6. 6.
    Tornblom H, Lindberg G, Nyberg B et al (2002) Full-thickness biopsy of the jejunum reveals inflammation and enteric neuropathy in irritable bowel syndrome. Gastroenterology 123:1972–1979PubMedCrossRefGoogle Scholar
  7. 7.
    Barbara G, Stanghellini V, De Giorgio R et al (2004) Activated mast cells in proximity to colonic nerves correlate with abdominal pain in irritable bowel syndrome. Gastroenterology 126:693–702PubMedCrossRefGoogle Scholar
  8. 8.
    Sun YN, Luo JY, Shang P et al (2005) Effects of N-methyl-d-aspartate receptor in visceral, hypersensitivity in rats with colonic inflammation. Zhong Nan Da Xue Xue Bao Yi Xue Ban 30:504–509PubMedGoogle Scholar
  9. 9.
    Erickson DR, Tomaszewski JE, Kunselman AR et al (2005) Do the National Institute of Diabetes and Digestive and Kidney Diseases cystoscopic criteria associate with other clinical and objective features of interstitial cystitis? J Urol 173:93–97PubMedCrossRefGoogle Scholar
  10. 10.
    Pimentel M, Chow EJ, Lin HC (2000) Eradication of small intestinal bacterial overgrowth reduces symptoms of irritable bowel syndrome. Am J Gastroenterol 95:3505–3506Google Scholar
  11. 11.
    Pimentel M, Chow EJ, Lin HC (2003) Normalization of lactulose breath testing correlates with symptom improvement in irritable bowel syndrome. A double-blind, randomized, placebo-controlled study. Am J Gastroenterol 98:412–419PubMedGoogle Scholar
  12. 12.
    Pimentel M, Park S, Kane SV et al (2006) The effect of a nonabsorbed oral antibiotic (rifaximin) on the symptoms of the irritable bowel syndrome: a randomized trial. Ann Intern Med 145:557–563PubMedGoogle Scholar
  13. 13.
    Sharara AI, Aoun E, Abdul-Baki H et al (2006) A randomized double-blind placebo-controlled trial of rifaximin in patients with abdominal bloating and flatulence. Am J Gastroenterol 101:326–333PubMedCrossRefGoogle Scholar
  14. 14.
    Lee HR, Low K, Chatterjee S et al (2006) In the treatment of IBS, the clinical response to rifaximin is determined by the normalization of the lactulose breath test. Am J Gastroenterol 110:A1223Google Scholar
  15. 15.
    Riordan SM, McIver CJ, Thomas DH et al (1997) Luminal bacteria and small-intestinal permeability. Scand J Gastroenterol 32:556–563PubMedCrossRefGoogle Scholar
  16. 16.
    Nieuwenhuijs VB, van Duijvenbode-Beumer H, Verheem A et al (1999) The effects of ABT-229 and octreotide on interdigestive small bowel motility, bacterial overgrowth and bacterial translocation in rats. Eur J Clin Invest 29:33–40PubMedCrossRefGoogle Scholar
  17. 17.
    Woodcock NP, Robertson J, Morgan DR et al (2001) Bacterial translocation and immunohistochemical measurement of gut immune function. J Clin Pathol 54:619–623PubMedCrossRefGoogle Scholar
  18. 18.
    Sant GR, Theoharides TC (1994) The role of the mast cell in interstitial cystitis. Urol Clin North Am 21:41–53PubMedGoogle Scholar
  19. 19.
    Weston AP, Biddle WL, Bhatia PS et al (1993) Terminal ileal mucosal mast cells in irritable bowel syndrome. Dig Dis Sci 38:1590–1595PubMedCrossRefGoogle Scholar
  20. 20.
    Peters KM, Diokno AC, Steinert BW (1999) Preliminary study on urinary cytokine levels in interstitial cystitis: does intravesical bacille Calmette-Guerin treat interstitial cystitis by altering the immune profile in the bladder? Urology 54(3):450–453PubMedCrossRefGoogle Scholar
  21. 21.
    Dunlap SP, Hebden J, Campbell E (2006) Abnormal intestinal permeability in subgroups of diarrhea-predominant irritable bowel syndromes. Am J Gastroenterol 101:1288–1294CrossRefGoogle Scholar
  22. 22.
    Warren JM, Horne LM, Hebel JR et al (2000) Pilot study of sequential oral antibiotics for the treatment of interstitial cystitis. J Urol 163:1685–1688PubMedCrossRefGoogle Scholar
  23. 23.
    Di Stefano M, Vos R, Janssens J et al (2003) Effect of tegaserod, a 5-HT4 receptor partial agonist, on interdigestive and postprandial gastrointestinal motility in healthy volunteers. Gastroenterology 126:A105412Google Scholar
  24. 24.
    Pimentel M, Soffer EE, Chow EJ, Kong Y, Lin HC (2002) Lower frequency of MMC is found in IBS subjects with abnormal lactulose breath test, suggesting bacterial overgrowth. Dig Dis Sci 47:2639–2643PubMedCrossRefGoogle Scholar
  25. 25.
    Weinstock LB, Tordorczuk JT, Fern SE et al (2006) Comprehensive SIBO therapy of IBS patients. Am J Gastroenterol 110:A1123Google Scholar
  26. 26.
    Weinstock LB, Tordorczuk JT, Fern SE et al (2006) Comprehensive SIBO therapy of functional bowel patients. Am J Gastroenterol 110:A1124Google Scholar
  27. 27.
    Huang DB, DuPont HL (2005) Rifaximin – a novel antimicrobial for enteric infections. J Infect 50:97–106PubMedCrossRefGoogle Scholar
  28. 28.
    Minocha A, Rashid S (1997) Reliability and reproducibility of breath hydrogen and methane in male diabetic subjects. Dig Dis Sci 42:672–676PubMedCrossRefGoogle Scholar
  29. 29.
    Eckburg PB, Bik EM, Bernstein CN et al (2005) Diversity of the human intestinal microbial flora. Science 308:1635–1638PubMedCrossRefGoogle Scholar
  30. 30.
    Strocchi A, Furne J, Ellis C et al (1994) Methanogens outcompete sulphate reducing bacteria for H2 in the human colon. Gut 35:1098–1101PubMedCrossRefGoogle Scholar
  31. 31.
    Levitt MD, Furne J, Springfield J et al (1999) Detoxification of hydrogen sulfide and methanethiol in the cecal mucosa. J Clin Invest 104:1107–1114PubMedCrossRefGoogle Scholar
  32. 32.
    Attene-Ramos MS, Wagner ED, Plewa MJ, Gaskins HR (2006) Evidence that hydrogen sulfide is a genotoxic agent. Mol Cancer Res 4:9–14PubMedCrossRefGoogle Scholar
  33. 33.
    Patacchini R, Santicioli P, Giuliani S, Maggi CA (2005) Pharmacological investigation of hydrogen sulfide (H2S) contractile activity in rat detrusor muscle. Eur J Pharmacol 509:171–177PubMedCrossRefGoogle Scholar
  34. 34.
    Patacchini R, Santicioli P, Giuliani S, Maggi CA (2004) Hydrogen sulfide (H2S) stimulates capsaicin-sensitive primary afferent neurons in the rat urinary bladder. Br J Pharmacol 142:31–34PubMedCrossRefGoogle Scholar
  35. 35.
    Boucher W, el-Mansoury M, Pang X, Sant GR, Theoharides TC (1995) Elevated mast cell tryptase in the urine of patients with interstitial cystitis. Br J Urol 76:94–100PubMedCrossRefGoogle Scholar
  36. 36.
    Chiang G, Patra P, Letourneau R, Jeudy S, Boucher W, Green M, Sant GR, Theoharides TC (2003) Pentosanpolysulfate (Elmiron) is a potent inhibitor of mast cell histamine secretion. Adv Exp Med Biol 539(Pt B):713–729PubMedGoogle Scholar
  37. 37.
    Coelho AM, Fioramonti J, Bueno L (2000) Systemic lipopolysaccharide influences rectal sensitivity in rats: role of mast cells, cytokines and vagus nerve. Am J Physiol Gastrointestinal Liver Physiol 279:G781–G790Google Scholar
  38. 38.
    Barbara G, Stanghellini V, De Giorgio R et al (2006) Functional gastrointestinal disorders and mast cells: implications for therapy. Neurogastroenterol Motil 18:6–17PubMedCrossRefGoogle Scholar
  39. 39.
    Pezzone MA, Liang R, Fraser MO (2005) A model of neural cross-talk and irritation in the pelvis: implications for the overlap of chronic pelvic pain disorders. Gastroenterology 128:1953–1954PubMedCrossRefGoogle Scholar
  40. 40.
    Theoharides TC (1996) The mast cell: a neuroimmunoendocrine master player. Int J Tissue React 18:1–21PubMedGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC 2007

Authors and Affiliations

  • Leonard B. Weinstock
    • 1
    • 2
  • Carl G. Klutke
    • 1
  • Henry C. Lin
    • 3
    • 4
  1. 1.Washington University School of MedicineSt. LouisUSA
  2. 2.St. LouisUSA
  3. 3.New Mexico VA Health Care SystemAlbuquerqueUSA
  4. 4.University of New MexicoAlbuquerqueUSA

Personalised recommendations